Holen Sie sich die Stockscreener-App
7.4364
2.16%
0.0164
Schlusskurs vom Vortag:
$7.42
Offen:
$7.44
24-Stunden-Volumen:
9,765
Relative Volume:
0.16
Marktkapitalisierung:
$45.07M
Einnahmen:
$100.44M
Nettoeinkommen (Verlust:
$-133.16M
KGV:
-0.2887
EPS:
-25.76
Netto-Cashflow:
$-94.85M
1W Leistung:
-3.07%
1M Leistung:
+28.69%
6M Leistung:
-32.98%
1J Leistung:
-44.45%
1-Tages-Spanne:
$7.44
$7.80
1-Wochen-Bereich:
$6.90
$8.65
52-Wochen-Spanne:
$5.005
$18.70
Atara Biotherapeutics Inc Stock (ATRA) Company Profile
Firmenname
Atara Biotherapeutics Inc
Sektor
Branche
Telefon
805-623-4211
Adresse
1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA
Vergleichen Sie ATRA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ATRA
Atara Biotherapeutics Inc
|
7.56 | 45.07M | 100.44M | -133.16M | -94.85M | -25.76 |
|
VRTX
Vertex Pharmaceuticals Inc
|
430.57 | 128.25B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
542.37 | 63.70B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
558.89 | 39.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
255.13 | 33.27B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
232.10 | 27.58B | 3.81B | -644.79M | -669.77M | -6.24 |
Atara Biotherapeutics Inc Stock (ATRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-11-09 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-11-09 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-11-09 | Herabstufung | Mizuho | Buy → Neutral |
| 2022-07-20 | Herabstufung | Citigroup | Neutral → Sell |
| 2022-07-13 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-07-13 | Herabstufung | Stifel | Buy → Hold |
| 2022-05-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-05-13 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-12-09 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-12-08 | Bestätigt | H.C. Wainwright | Buy |
| 2020-11-10 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-30 | Eingeleitet | Evercore ISI | Outperform |
| 2020-06-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-04-23 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-11-08 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-09-27 | Herabstufung | Goldman | Neutral → Sell |
| 2019-09-16 | Herabstufung | Jefferies | Buy → Hold |
| 2019-06-04 | Hochstufung | Citigroup | Sell → Neutral |
| 2019-05-30 | Eingeleitet | ROTH Capital | Buy |
| 2019-05-23 | Eingeleitet | Stifel | Buy |
| 2019-01-23 | Eingeleitet | Mizuho | Buy |
| 2018-04-10 | Eingeleitet | JP Morgan | Overweight |
| 2018-03-16 | Eingeleitet | Guggenheim | Neutral |
| 2018-03-05 | Bestätigt | Jefferies | Buy |
| 2018-02-28 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-02-15 | Herabstufung | Citigroup | Neutral → Sell |
| 2018-01-03 | Hochstufung | Citigroup | Sell → Neutral |
| 2017-10-06 | Fortgesetzt | Goldman | Neutral |
Alle ansehen
Atara Biotherapeutics Inc Aktie (ATRA) Neueste Nachrichten
FDA lifts clinical hold on Atara’s Ebvallo - The Pharma Letter
FDA Lifts Hold on Atara’s EBVALLO Program - TipRanks
Atara Does An About Face As FDA Lifts Ebvallo Hold - insights.citeline.com
(ATRA) Investment Analysis - news.stocktradersdaily.com
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Shares Fly 30% But Investors Aren't Buying For Growth - simplywall.st
FDA Lifts Hold on Atara Biotherapeutics' Ebvallo Program | ATRA Stock News - GuruFocus
Atara Biotherapeutics Provides Regulatory Updates on EBVALLO™ (tabelecleucel) | ATRA Stock News - GuruFocus
Atara Biotherapeutics Says FDA Lifts Clinical Hold Enabling Resumption Of Clinical Trials - marketscreener.com
Atara Biotherapeutics Provides Regulatory Updates on EBVALLO™ (tabelecleucel) - Business Wire
Atara Biotherapeutics, Inc. Provides Regulatory Updates on EBVALLO?? (Tabelecleucel) - marketscreener.com
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Shares Acquired by Geode Capital Management LLC - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Head-To-Head Contrast: Atara Biotherapeutics (NASDAQ:ATRA) and Creative Medical Technology (NASDAQ:CELZ) - Defense World
(ATRA) On The My Stocks Page - news.stocktradersdaily.com
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Trial misses sink cancer stocks in Q1: Mersana, Cargo, Mural fall - BioWorld MedTech
Layoff Tracker: Spark Lays Off 298 Employees - BioSpace
Atara Biotherapeutics stock hits 52-week low at $5.3 - Investing.com
Atara Biotherapeutics stock hits 52-week low at $5.3 By Investing.com - Investing.com UK
How the (ATRA) price action is used to our Advantage - news.stocktradersdaily.com
Atara Biotherapeutics IncOn March 31, Entered Amendment To Commercialization Agreement With Pierre FabreSEC Filing - marketscreener.com
Epstein-Barr Virus (EBV) Market Growth 2025: Trends, Consumer - openPR.com
Atara Biotherapeutics Faces Potential Liquidation: Strategic Decisions Crucial for Investor Outcomes - MSN
Long Term Trading Analysis for (ATRA) - news.stocktradersdaily.com
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Atara Biotherapeutics (NASDAQ:ATRA) Stock Crosses Below 50 Day Moving Average – Should You Sell? - Defense World
Multiple Sclerosis Treatment Market 2034: EMA, PDMA, FDA Approval, Clinical Trials, Medication, Epidemiology, Prevalence, Therapies and Companies by DelveInsight - The Globe and Mail
(ATRA) Investment Report - news.stocktradersdaily.com
Atara Biotherapeutics (ATRA) Moves to Buy: Rationale Behind the Upgrade - Yahoo Finance
Atara Biotherapeutics (NASDAQ:ATRA) Given Buy Rating at Canaccord Genuity Group - Defense World
Atara Biotherapeutics: Strategic Focus on Ebvallo BLA Resubmission and Market Position Enhancement - TipRanks
SNOA's Wound Care Products Get Regulatory Clearance, LFMD's Q4 Revenue Soars, ATRA On Watch - RTTNews
Atara Biotherapeutics: Q4 Earnings Snapshot - The Bakersfield Californian
Atara Biotherapeutics (ATRA) Reports Q4 Loss, Tops Revenue Estimates - MSN
Atara Biotherapeutics Reports 2024 Financial Results - TipRanks
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Operational Progress - BioSpace
Atara Biotherapeutics Inc. (ATRA) reports earnings - Quartz
Atara Biotherapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Lacklustre Performance Is Driving Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) 27% Price Drop - Simply Wall St
Finanzdaten der Atara Biotherapeutics Inc-Aktie (ATRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Atara Biotherapeutics Inc-Aktie (ATRA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Hyllengren Eric J | EVP, CFO and COO |
Mar 03 '25 |
Sale |
7.00 |
1,211 |
8,473 |
56,231 |
| Henrich Jill | EVP, Chief Regulatory Officer |
Mar 03 '25 |
Sale |
7.00 |
1,059 |
7,410 |
18,679 |
5.73%
1.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):